Medical strategies to adopt in the face of regulatory changes to cancer drug management (removal from or non-registration on the “liste en sus”)
Crossref DOI link: https://doi.org/10.1007/s10269-017-2733-x
Published Online: 2018-01-11
Published Print: 2017-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Albin, N.
License valid from 2017-11-01